Development of a theranostic agent for imaging and treatment of neuroendocrine tumours, using Positron|Emission Tomography and Peptide Receptor Radionuclide Therapy, based on a new generation of|radiolabelled somatostatin analogues

Schrift Standard Fett
Login

Forschungsstelle

INNOSUISSE

Projektnummer

18282.2 PFLS-LS

Projekttitel

Development of a theranostic agent for imaging and treatment of neuroendocrine tumours, using Positron|Emission Tomography and Peptide Receptor Radionuclide Therapy, based on a new generation of|radiolabelled somatostatin analogues

Projekttitel Englisch

Development of a theranostic agent for imaging and treatment of neuroendocrine tumours, using Positron Emission Tomography and Peptide Receptor Radionuclide Therapy, based on a new generation of radiolabelled somatostatin analogues

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung		-	-
Abstract		-	-

Erfasste Texte

Kategorie	Text
Kurzbeschreibung (Deutsch)	Development of a theranostic agent for imaging and treatment of neuroendocrine tumours, using Positron\|Emission Tomography and Peptide Receptor Radionuclide Therapy, based on a new generation of\|radiolabelled somatostatin analogues
Kurzbeschreibung (Englisch)	Development of a theranostic agent for imaging and treatment of neuroendocrine tumours, using Positron Emission Tomography and Peptide Receptor Radionuclide Therapy, based on a new generation of radiolabelled somatostatin analogues
Abstract (Deutsch)	The project targets the development of the novel somatostatin (SST) analogue G02113, with high affinity to\|the SST receptor subtypes 2 and 5, as a theranostic agent for the management of patients suffering\|from neuroendocrine tumours (NETs). G02113 labelled with 68Ga will be developed as a Positron Emission\|Tomography (PET) imaging tracer for diagnostic imaging and therapy follow-up of NETs, while the same\|compound labelled with 177Lu will be developed as a therapeutic agent for Peptide Receptor Radionuclide\|Therapy (PRRT).
Abstract (Englisch)	The project targets the development of the novel somatostatin (SST) analogue G02113, with high affinity to\|the SST receptor subtypes 2 and 5, as a theranostic agent for the management of patients suffering\|from neuroendocrine tumours (NETs). G02113 labelled with 68Ga will be developed as a Positron Emission\|Tomography (PET) imaging tracer for diagnostic imaging and therapy follow-up of NETs, while the same\|compound labelled with 177Lu will be developed as a therapeutic agent for Peptide Receptor Radionuclide\|Therapy (PRRT).